Tecentriq (atezolizumab)

P1, N=18, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed

P2, N=40, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting

P1/2, N=29, Recruiting, University of Florida | Trial primary completion date: Jun 2025 --> Dec 2025

P2, N=48, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026

However, a growing number of additional PD-1/PD-L1 inhibitors, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, are currently under investigation, offering new possibilities for the expansion of treatment options...Additionally, it explores key challenges such as primary and acquired resistance, limited efficacy in microsatellite-stable (MSS) CRC, and the complexities of combination strategies aimed at enhancing immunotherapeutic responses. By addressing these obstacles and highlighting prospects, this review provides insights into the evolving landscape of PD-1/PD-L1-targeted therapies in CRC and their potential to improve patient outcomes.

In the IMpower010 trial, atezolizumab improved DFS compared to best supportive care (BSC) in resected stage II-IIIA NSCLC, with a hazard ratio (HR) of 0.66 (95% CI 0.50-0.88) for patients with PD-L1 expression ≥1% and 0.79 (95% CI 0.64-0.96) for the overall stage II-IIIA population. In the PEARLS/KEYNOTE-091 trial, pembrolizumab also demonstrated a DFS benefit over a placebo for patients with stage IB-IIIA disease (HR 0.76; 95% CI 0.63-0.91), with a median DFS of 53.6 months versus 42.0 months...The integration of immunotherapy in the adjuvant setting represents a significant advancement in the management of resectable NSCLC. This review aims to provide an overview of the current evidence supporting the use of ICIs in the adjuvant treatment of NSCLC, focusing on treatment efficacy, safety profiles, and ongoing research into biomarkers and combination therapies.

Notably, higher PD-L1 levels post-de-glycosylation were significantly associated with favorable responses to ICB treatments, particularly among patients receiving pembrolizumab and atezolizumab. These results underscore the clinical importance of deglycosylation in enhancing PD-L1 detection accuracy, enabling more precise patient selection for ICB therapies. Incorporating deglycosylation into PD-L1 assessment protocols may improve treatment outcomes for TNBC patients and establish deglycosylated PD-L1 as a more reliable biomarker for ICB therapy response.

The authors first proposed the opinion that the incidence of serious NAEs in immunotherapy patients was significantly higher than in other groups, providing a novel direction for research.

High CTA expression in resected SBNET is independently associated with improved survival. Epigenetic dysregulation and immune activation in CTA-enriched tumor regions highlight the potential for combination epigenetic modifiers and immunotherapy in future trials.

P1/2, N=35, Completed, Inovio Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2025 --> May 2025

A total of 1,469 patients who underwent hepatectomy and 525 patients who received systemic chemotherapy, including lenvatinib, atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, as first-line treatment were analyzed. In the PSM analysis, no significant differences were observed between the BR1 and BR2 groups for hepatectomy and systemic chemotherapy. The intrahepatic tumor number for hepatectomy and the intrahepatic maximal tumor size for systemic chemotherapy are significant risk factors for BR2 patients, highlighting the characteristics of each treatment and the potential for selecting the optimal modality.

P1, N=16, Active, not recruiting, Centre Hospitalier Universitaire Vaudois | Recruiting --> Active, not recruiting

P4, N=40, Not yet recruiting, Icahn School of Medicine at Mount Sinai

P3, N=49, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

P1, N=102, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

P1, N=47, Recruiting, Boehringer Ingelheim | Trial primary completion date: Aug 2025 --> Dec 2025

P1, N=9, Not yet recruiting, University of California, Irvine

In patients with HCC characterised by limited resectability undergoing Atezo/Bev, vascular invasion, in addition to liver function, is a critical prognostic determinant of tumour progression.

The aim of this study is to investigate whether the combination therapy of Tumor-Suppressing Multi-Enterobacteria (TSME) and PD-L1 inhibitor (atezolizumab) can improve the efficacy of immunotherapy-resistant hepatocellular carcinoma...Tumor volume was lower in the αPD-1+TSME group than in the monotherapy group. Anti-tumor TSME combined with αPD-1 mAb may be a new strategy to improve the sensitivity of immune-resistant patients with advanced hepatocellular carcinoma to anti-PD-1 immunotherapy.

The ImBrave 150 trial successfully demonstrated that overall survival (OS) and progression-free survival (PFS) was improved among patients treated with atezolizumab combined with bevacizumab (AB) compared with patients treated with sorafenib. However, the retrospective design and the lack of a control group represent important limitations. Our real-life study yielded OS and PFS durations similar to those reported in the ImBrave 150 trial.

P=N/A, N=107, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

P1/2, N=272, Active, not recruiting, Hoffmann-La Roche | Trial completion date: May 2026 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

P1, N=272, Completed, Genentech, Inc. | Active, not recruiting --> Completed

Additionally, the IRLS score predicted responses to paclitaxel chemotherapy, and the low-risk group exhibited higher immune cell infiltration (P < 0.05), showing significant negative correlations with CD8A, PD-L1, tumor mutational burden (TMB), and neoantigen load (NAL). In immune checkpoint inhibitor (ICI) treatment cohorts, low IRLS scores were associated with improved response rates to atezolizumab. Our findings suggest that the IRLS model serves as a novel biomarker for prognostic stratification and personalized therapeutic decision-making in breast cancer.

P2, N=50, Not yet recruiting, M.D. Anderson Cancer Center

P1, N=57, Completed, Genentech, Inc. | Active, not recruiting --> Completed | N=232 --> 57 | Trial completion date: Mar 2026 --> Jun 2025 | Trial primary completion date: Mar 2026 --> Jun 2025

Atezolizumab plus bevacizumab led to tumor regression, but following a brain infarction, the therapy was switched to durvalumab plus tremelimumab, and durable remission was achieved despite programmed death-ligand 1 (PD-L1) negativity. This case underscores the potential application of immune checkpoint inhibitors (ICIs) in the treatment of multiple primary malignancies and highlights the need for further research on predictive biomarkers and optimal combination strategies. This case also raises important questions regarding the mechanisms of ICI efficacy in PD-L1-negative malignancies, and suggests that immune synergy between coexisting tumors may enhance antitumor responses.

OS was similar in both arms, but docetaxel plus ramucirumab resulted in favorable ORR and PFS. The 2-year OS rates suggested that atezolizumab might enhance the efficacy of post-study cytotoxic chemotherapy; however, interpretation of the data was limited by the small sample size.

P1/2, N=40, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Jun 2025 --> Sep 2025

P2, N=29, Recruiting, University of Arizona | Trial completion date: May 2025 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025

P=N/A, N=28, Not yet recruiting, RenJi Hospital

The CRAPT-M model demonstrated robust OS prediction, offering a valuable tool for prognosis estimation and clinical decision-making in advanced HCC patients receiving AB.

Included patients were receiving neoadjuvant chemoimmunotherapy (nivolumab or pembrolizumab with platinum-based doublet chemotherapy) or adjuvant chemoimmunotherapy (atezolizumab or pembrolizumab with or without chemotherapy) after the US Food and Drug Administration approval of these therapies. This retrospective cohort study found that chemoimmunotherapy was associated with favorable clinical DMFS outcomes in patients with resectable NSCLC. The findings highlight the need to address barriers to broader adoption of chemoimmunotherapy.

P2, N=63, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2027 --> Oct 2029 | Trial primary completion date: Jun 2025 --> Oct 2027

P1, N=0, Withdrawn, University of Kansas Medical Center | N=54 --> 0 | Trial completion date: Jul 2027 --> Jul 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2027 --> Jul 2024

P=N/A, N=120, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Sep 2027 --> Sep 2029 | Trial primary completion date: Sep 2025 --> Sep 2029

P1, N=10, Active, not recruiting, University of Southern California | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2026

P2, N=97, Completed, GERCOR - Multidisciplinary Oncology Cooperative Group | Active, not recruiting --> Completed

P2, N=115, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jan 2025 --> Jul 2025

P3, N=132, Recruiting, Shandong Cancer Hospital and Institute | Trial completion date: Mar 2028 --> Jul 2028 | Trial primary completion date: Mar 2027 --> Jul 2027

P1, N=12, Recruiting, Stony Brook University | Trial completion date: Aug 2026 --> Aug 2029 | Trial primary completion date: Aug 2026 --> Aug 2027

P1/2, N=80, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025